# QV Bioelectronics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qv-bioelectronics

- Industry: Medical Devices & Equipment
- Headquarters: UK
- Website: www.qvbio.co.uk/
- Total disclosed funding: $1.3M
- Latest round: Seed (May 16, 2022)
- Investors on record: 4

## About

QV Bioelectronics Ltd., based in the UK, specializes in innovative bioelectronic devices for cancer treatment, focusing on glioblastoma. Their flagship product offers a therapeutic solution that disrupts cancer cell growth cycles while aiming to improve patient quality of life. Founded in 2018 in Cheshire, UK, QV Bioelectronics Ltd. develops bioelectronic devices targeting cancer treatment. The company is led by CEO Christopher Bullock. In July 2026, QV Bioelectronics Ltd. raised an undisclosed amount from PXN Group. QV Bioelectronics focuses on developing bioelectronic devices for cancer treatment, particularly glioblastoma. Their primary product, GRACE, uses Electric Field Therapy to target tumor resection margins, slowing tumor progression by disrupting cancer cell growth cycles. The company aims to expand its product pipeline to address additional neuro-oncology indications in markets such as North America and Europe. The revenue model for QV Bioelectronics is based on the commercialization of its medical devices, notably the GRACE device. It generates revenue through direct partnerships with healthcare institutions, including hospitals and cancer treatment centers. The sales may involve one-time purchases or recurring fees related to device usage and maintenance, catering primarily to healthcare professionals managing glioblastoma treatment.In March 2023, QV Bioelectronics Ltd. raised GBP 860,000 in grant funding from Innovate UK to support its product development efforts, specifically for human applications. The company plans to launch new products targeting glioblastoma and expand into North American and European markets. This funding will aid in bringing their innovative solutions to broader healthcare markets.

## Funding rounds

- Seed, May 16, 2022 — SOSV
- Seed, Apr 3, 2021, $0.9M — Catapult Ventures Group, SOSV, Consilience Ventures
- Seed, Jul 29, 2020, $0.1M — SOSV, RebelBio
- Seed, Nov 8, 2019, $0.2M — SOSV
- Seed, Oct 7, 2018, $0.1M — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- RebelBio — Seed
- Catapult Ventures Group (https://capitalatlas.ai/funds/catapult-ventures-group) — Seed
- Consilience Ventures — Seed